glp 1 effect on bone density Effects of Glucagon-Like Peptide-1 receptor agonists health in people living with obesity | Osteoporosis International Glp 1 Agonists Bone Density

As the first anti-obesity drug targeting multiple receptors, tirzepatide (Zepbound, Eli Lilly), a dual GIPR/GLP-1R agonist, was approved by the FDA in 2022

Its the same technology used in oral salmon calcitonin formulations that actually got FDA approval

The adults segment dominated the GLP-1 targeted peptide weight loss drugs market in 2024 because obesity prevalence is highest among adults, making them the primary target population for these therapies

Firstly, our strategy does not involve the expression of 3CD protease and therefore eliminates 3CD-caused cellular toxicity and/or incomplete cleavage of P1 by 3CD